Use of argatroban as anticoagulation for cardiopulmonary bypass during heart transplantation: A case report Authors: Marika Faggioli, Daniela Bacich, Chiara Tessari, Fabio Zanella, Demetrio Pittarello, Annalisa Angelini, Augusto D’Onofrio, Vincenzo Tarzia, Gerosa Gino Published: 2026 ABSTRACT AbstractBackgroundHeparin-induced thrombocytopenia rules out the possibility of adopting heparin for cardiopulmonary bypass. To overcome this problem two anticoagulants can be used: argatroban and bivalirudin.Case presentationWe report on the adoption of argatroban during cardiopulmonary bypass for heart transplantation in a patient affected by HIT, previously implanted with a left ventricular assist device. Despite appropriate dosing, anticoagulation reversal proved ineffective, resulting in uncontrollable coagulopathy and fatal haemorrhage.ConclusionsArgatroban could be an effective option for selected patients but more studies and particular attention are required, especially in patients with previous left ventricular assist device implantation.Keywords: Heart transplantation, Haemorrhage, Argatroban, Bivalirudin, Heparin induced thrombocytopenia. Background Heparin-induced thrombocytopenia (HIT) is a significant problem in patients who undergo cardiac surgery, considering the requirement of using heparin during cardiopulmonary bypass (CPB). As an alternative to heparin, two other anticoagulants are available: bivalirudin and argatroban. Bivalirudin is an inhibitor of thrombin, a factor within the coagulation cascade essential to thrombus formation. Unlike heparin, bivalirudin is a direct inhibitor, which binds to thrombin and directly interrupts the coagulation cascade. Also, it does not combine platelet factor IV, and thus does not share cross-reactivity with antibodies in patients with a history of HIT. Primarily excretion of this medication is via the kidneys, therefore the patient’s renal function requires monitoring [1]. Plasmatic half-life of bivalirudin is 25 min [2]. Argatroban is a synthetic complex based on the structure of L-arginine. It is a direct inhibitor of thrombin, that reversibly ties the active site of thrombin and inhibits its downstream action. It is metabolized primarily by the liver (cytochrome P450), therefore interactions with other medications may occur [3]. Plasmatic half-life of argatroban is 45 min [2]. For both medications there is no reversal agent. During heart surgery, when restoration of the coagulation setting is needed, the continuous infusion of argatroban or bivalirudin must be stopped, waiting for the anticoagulant effect to gradually decline. The end of the medication’s effect depends on its half-life. We present the case of a patient affected by HIT in whom argatroban was used instead of heparin for anticoagulation during cardiopulmonary bypass. The patient experienced severe, unreversible coagulopathy, leading to death because of severe haemorrhage. Case presentation The patient was 39 years-old male (83 kg) was affected by inflammatory cardiomyopathy with autoimmune aetiology and severe left ventricle dilatation and dysfunction, severe functional mitral regurgitation. Right ventricular function was moderately reduced but not severely impaired, as documented by preoperative echocardiography. Comorbidities included cognitive impairment, symptomatic hypoglycaemia, and minor previous surgical history. For these reasons he had previously undergone S-ICD (Subcutaneous Implantable Cardioverter-Defibrillator,) and LVAD (Left Ventricular Assist Device) implantation, which was performed in 2022, and heart transplantation in December 2023. During follow up he developed an infection of the LVAD driveline exit site, which was unresponsive to medical treatment, with no evidence of systemic infection, sepsis or contribute to the observed coagulopathy or bleeding complications. For this reason, the patient’s status on the heart transplantation waiting list was upgraded from standard to urgent. Following the detection of a depleted platelet count (122 × 10^9/l), he was found to have a positivity to anti heparin antibodies-PF4 (0.987 OD), so heparin avoidance was considered mandatory in this high-risk context. Therefore, fondaparinux (5 mg alternate to 2,5 mg, adapted according to kidney function) was chosen as anticoagulation therapy instead of heparin. Preoperative values of kidney and liver function were mildly impaired: creatinine 128 µmol/l, eGFR 60 ml/min, GOT 41 U/l, GPT 32 U/l. Preoperative CBC and coagulation profile were the following: aptt ratio 1,39, INR 1,78, WBC 4,41 × 10^9 g/L, RBC 3,22 × 10^12/L, Hb 84 g/L. Patient, at the time of the events, was taking these medications: daptomycin, Piperacillin/tazobactam (for the infection of exit site of driveline), fondaparinux, Aldactone, doxazosin, amiodarone, furosemide, potassium and iron supplements, lansoprazole, ramipril, atorvastatin, allopurinol and aerosol with salbutamol and ipratropium bromide. As a suitable donor was found, the patient was prepared for heart transplantation. Surgery was difficult from the beginning, it was a redo surgery, LVAD implantation was performed by sternotomy, so there were a lot of adhesions. Surgery started on 28th December 2023 at 1:55 am and finished at 11:10 pm. Because of HIT, argatroban was selected as anticoagulation for CPB. CBP was performed using a Maquet PMP oxygenator and a HLMS Spectrum 3 T circuit, cannulation site for CEC was perfomed from femoral artery and vein and superior cava vein. The patient received an initial 9 mg bolus of argatroban (at 4 am), followed by continuous infusion titrated between 5 and 10 mcg/kg/min, which continues until 7:30 am. The baseline ACT was 178 s, and the maximum ACT exceeded 1000 s (Fig. 1). ACT values (seconds) in function of time of intervention (minutes) and argatroban dose (mcg/kg/min) Argatroban was discontinued three hours and thirty minutes after initiation of the infusion, at which time the ACT was 1000 s. Concomitantly, the aortic cross-clamp was removed and procoagulant therapy was initiated. CPB time was 282 min, aortic cross-clamp time was 105 min, and total argatroban infusion time was 210 min. After declamping, adequate surgical hemostasis was not achieved. Consequently, veno-arterial femoro-femoral ECMO was initiated, together with massive transfusion and pro-coagulant therapy as followed: TRANEXAMIC ACID: 2 g H 1:30 + 5 g TRANEXAMIC ACID: 2 g H 1:30 + 5 g FIBRINOGEN: 46 g FIBRINOGEN: 46 g COAGULATION FACTORS: 8400 UI COAGULATION FACTORS: 8400 UI COMPLEX OF FACTORS IX-II-X: 12,000 UI COMPLEX OF FACTORS IX-II-X: 12,000 UI FACTOR VII: 33 mg FACTOR VII: 33 mg PLASMA: 12 units PLASMA: 12 units PLATELETS: 9 units PLATELETS: 9 units PRBC: 47 units PRBC: 47 units In order to enhance drug clearance, intraoperative continuous veno-venous hemodiafiltration (CVVHDF - ST-150) was settled. aPTT measured after initiation was 8.10 s, but haemostasis did not improve over time. Despite all the adopted measures, satisfactory coagulation parameters could not be restored. After twelve hours of haemostasis, the patient was transferred to the ICU, where he developed haemorrhagic liver disease and multiorgan failure, and subsequently died because of severe haemorrhage, as described by the autopsy report. Discussion and conclusions This case highlights the complexity of managing anticoagulation with argatroban in LVAD patients undergoing CPB for heart transplantation. LVAD patients require chronic anticoagulation (warfarin or heparin) to prevent pump thrombosis. Anticoagulant treatment with heparin may promote the development of anti-heparin antibodies: PF4 is released upon platelet activation, it can bind heparin and may induce the formation of antibodies specific for this complex [4]. Additionally, impairment of right ventricular function, which is common in LVAD patients, may provoke a decline in liver function, which results in altered metabolism of many medications, including argatroban. The employment of argatroban could be the right choice for patients with HIT and renal failure, as demonstrated by Edwards et al. [5], with care of using a dose of this medication into CPB circuit during priming. Green et al. [6] showed a specific case of argatroban employment during CPB in heart transplantation with successful outcome, but they concluded that more studies would be needed to establish the right dose and monitoring of anticoagulation effect. In our specific case, despite the adequate dose of argatroban and the adoption of multiple pro-coagulant medications, we were not able to return to preoperative coagulation parameters. Probably, it is useful to always have a measurable ACT value and also a coordination between surgical and pharmacological timing, to interrupt argatroban in time to have the correct coagulation setup, therefore earlier discontinuation and tighter ACT-guided titration of argatroban may improve safety. Novel anticoagulation strategies for extracorporeal circulation are under development, one of these is the using a combination of cangrelor and heparin in case of HIT as described by Del Vecchio et al. [7]. Furthermore, Koster et al. described a protocol of using tirofiban (short acting platelet glycoprotein IIb-IIIa antagonist) before unfractionated heparin during CPB in patients with HIT and renal impairment, which shown no increase of haemorrhage risk or thromboembolic events [8]. In conclusion, argatroban could be an effective option for selected patients but more studies and particular attention are required, especially if it is taken into consideration for patients with previous LVAD implantation who are listed for heart transplantation. Abbreviations Heparin induced thrombocytopenia Cardiopulmonary bypass Left ventricular assist device Subcutaneous Implantable Cardioverter-Defibrillator Intraoperative continuous veno-venous hemodiafiltration Packed Red Blood Cells Author contributions FM, conceptualization, data collection, draft preparation. DB and CT: writing, review and editing. FZ, DP and AA: data collection, review and editing. AD VT and GG: supervision, resources and review. Funding This paper received no specific grant from any funding agency, commercial or not-for-profit sectors. Data availability The data used are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Ethics approval Approval was obtained from our institution’s ethical committee (prot. 0020405/2023). Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data used are available from the corresponding author upon reasonable request.